These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 27003398)
21. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. McFarlane C; Plummer E; Thomas M; Hennebry A; Ashby M; Ling N; Smith H; Sharma M; Kambadur R J Cell Physiol; 2006 Nov; 209(2):501-14. PubMed ID: 16883577 [TBL] [Abstract][Full Text] [Related]
22. Myostatin's marvels: From muscle regulator to diverse implications in health and disease. Sharma S; Patil AS Cell Biochem Funct; 2024 Aug; 42(6):e4106. PubMed ID: 39140697 [TBL] [Abstract][Full Text] [Related]
23. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Souza TA; Chen X; Guo Y; Sava P; Zhang J; Hill JJ; Yaworsky PJ; Qiu Y Mol Endocrinol; 2008 Dec; 22(12):2689-702. PubMed ID: 18927237 [TBL] [Abstract][Full Text] [Related]
24. Possible role of TIEG1 as a feedback regulator of myostatin and TGF-beta in myoblasts. Miyake M; Hayashi S; Iwasaki S; Chao G; Takahashi H; Watanabe K; Ohwada S; Aso H; Yamaguchi T Biochem Biophys Res Commun; 2010 Mar; 393(4):762-6. PubMed ID: 20171187 [TBL] [Abstract][Full Text] [Related]
31. TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. Dietz HC J Clin Invest; 2010 Feb; 120(2):403-7. PubMed ID: 20101091 [TBL] [Abstract][Full Text] [Related]
32. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy. Patel K; Macharia R; Amthor H Acta Myol; 2005 Dec; 24(3):230-41. PubMed ID: 16629058 [TBL] [Abstract][Full Text] [Related]
33. Development of novel activin-targeted therapeutics. Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825 [TBL] [Abstract][Full Text] [Related]
34. Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia. Ojima C; Noguchi Y; Miyamoto T; Saito Y; Orihashi H; Yoshimatsu Y; Watabe T; Takayama K; Hayashi Y; Itoh F Cancer Sci; 2020 Aug; 111(8):2954-2964. PubMed ID: 32519375 [TBL] [Abstract][Full Text] [Related]
35. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling. Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493 [TBL] [Abstract][Full Text] [Related]
36. TGF-β superfamily signaling in muscle and tendon adaptation to resistance exercise. Gumucio JP; Sugg KB; Mendias CL Exerc Sport Sci Rev; 2015 Apr; 43(2):93-9. PubMed ID: 25607281 [TBL] [Abstract][Full Text] [Related]
37. Myostatin: a therapeutic target for skeletal muscle wasting. Roth SM; Walsh S Curr Opin Clin Nutr Metab Care; 2004 May; 7(3):259-63. PubMed ID: 15075916 [TBL] [Abstract][Full Text] [Related]